약물유전체학 기술 시장 : 산업 규모, 점유율, 동향, 기회, 예측, 치료 분야별, 기술별, 지역별, 경쟁별(2020-2030년)

Global Pharmacogenomics Technology market was valued at USD 7.60 billion in 2024 and is projected to experience robust growth, reaching significant milestones by 2030 with a compound annual growth rate (CAGR) of 8.45% over the forecast period. As the healthcare landscape continues to evolve, personalized medicine is becoming central to enhancing patient outcomes and minimizing adverse drug reactions. At the forefront of this shift is pharmacogenomics (PGx), a transformative field that enables the customization of drug therapies based on an individual's genetic profile.

Pharmacogenomics, a specialized area within genomics, studies how genetic variations influence drug metabolism and response. Given that every individual's DNA is unique, this approach facilitates the identification of genetic markers that predict how patients will respond to specific medications. As a result, pharmacogenomics allows healthcare providers to tailor treatments for maximum effectiveness and safety, moving away from generalized treatment models toward precision medicine.

Key Market Drivers

Increasing Prevalence of Chronic Diseases

The rising incidence of chronic diseases globally is a primary catalyst for the growth of the pharmacogenomics technology market. Conditions such as cancer, cardiovascular disease, diabetes, and chronic respiratory disorders remain leading causes of mortality, collectively responsible for over 41 million deaths annually. Additionally, approximately one in three adults worldwide live with multiple chronic conditions, necessitating long-term and highly personalized treatment plans.

In 2022 alone, there were an estimated 20 million new cancer cases and 9.7 million related deaths, while 53.5 million individuals were within five years of a cancer diagnosis. These figures highlight the growing burden of chronic illness and the need for more effective and individualized therapeutic approaches.

Traditional treatment models often rely on trial-and-error prescribing, which can result in suboptimal outcomes and increased healthcare costs. Pharmacogenomics offers a solution by matching patients with the most appropriate medications based on their genetic makeup, thereby improving therapeutic efficacy and reducing adverse drug events. The economic implications are also significant-pharmacogenomics supports cost containment by decreasing the use of ineffective treatments and reducing hospitalizations due to drug-related complications. This makes it an attractive proposition for both public health systems and private payers, fueling broader industry adoption.

Key Market Challenges

Complexity of Data and Integration Barriers

One of the principal challenges in the pharmacogenomics sector lies in managing and integrating the vast amounts of complex data generated through genomic sequencing and drug response studies. Accurate prediction of drug efficacy and safety hinges on the effective analysis of these datasets, which requires sophisticated bioinformatics tools and specialized expertise. However, such capabilities are not uniformly distributed across global healthcare systems, creating disparities in implementation and limiting market penetration in certain regions.

Key Market Trends

Advancements in Technology Driving Market Evolution

Technological innovation continues to be a major growth enabler for the pharmacogenomics industry. High-throughput techniques such as next-generation sequencing (NGS) have revolutionized the field by enabling rapid, cost-effective analysis of entire genomes or targeted gene regions. NGS has dramatically improved the accuracy and efficiency of detecting clinically relevant genetic variants, expanding the potential for personalized drug therapy.

The proliferation of genomic data generated through NGS has necessitated the adoption of advanced analytical solutions. Machine learning and artificial intelligence (AI) have emerged as vital tools for interpreting complex datasets, identifying patterns, and predicting individual drug responses. These technologies are facilitating more informed decision-making for clinicians and accelerating the integration of pharmacogenomics into routine clinical practice.

Key Market Players

• QIAGEN N.V.
• GE HealthCare,
• Agilent Technologies, Inc.
• F. Hoffmann-La Roche Ltd
• FOUNDATION MEDICINE, INC.
• Thermo Fisher Scientific Inc.
• Leica Biosystems Nussloch GmBH,
• Pfizer Inc.

Report Scope:

In this report, the Global Pharmacogenomics Technology Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Pharmacogenomics Technology Market, By Therapeutics Area:

• Oncology
• Neurological Disorders
• Cardiovascular Disease
• Immunological Disorders
• Infectious Diseases
• Others

Pharmacogenomics Technology Market, By Technology:

• PCR
• In-situ Hybridization
• Immunohistochemistry
• Sequencing
• Others

Pharmacogenomics Technology Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Pharmacogenomics Technology Market.

Available Customizations:

Global Pharmacogenomics Technology market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Pharmacogenomics Technology Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Therapeutic Area (Oncology (Lung Cancer, Breast Cancer, Colorectal Cancer, Cervical Cancer, Others), Neurological Disorders, Cardiovascular Disease, Immunological Disorders, Infectious Diseases, Others)
  • 5.2.2. By Technology (PCR, In-situ Hybridization, Immunohistochemistry, Sequencing, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Pharmacogenomics Technology Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Therapeutics Area
  • 6.2.2. By Technology
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Pharmacogenomics Technology Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Therapeutics Area
      • 6.3.1.2.2. By Technology
  • 6.3.2. Canada Pharmacogenomics Technology Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Therapeutics Area
      • 6.3.2.2.2. By Technology
  • 6.3.3. Mexico Pharmacogenomics Technology Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Therapeutics Area
      • 6.3.3.2.2. By Technology

7. Europe Pharmacogenomics Technology Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Therapeutics Area
  • 7.2.2. By Technology
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Pharmacogenomics Technology Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Therapeutics Area
      • 7.3.1.2.2. By Technology
  • 7.3.2. United Kingdom Pharmacogenomics Technology Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Therapeutics Area
      • 7.3.2.2.2. By Technology
  • 7.3.3. Italy Pharmacogenomics Technology Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Therapeutics Area
      • 7.3.3.2.2. By Technology
  • 7.3.4. France Pharmacogenomics Technology Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Therapeutics Area
      • 7.3.4.2.2. By Technology
  • 7.3.5. Spain Pharmacogenomics Technology Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Therapeutics Area
      • 7.3.5.2.2. By Technology

8. Asia-Pacific Pharmacogenomics Technology Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Therapeutics Area
  • 8.2.2. By Technology
  • 8.2.3. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Pharmacogenomics Technology Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Therapeutics Area
      • 8.3.1.2.2. By Technology
  • 8.3.2. India Pharmacogenomics Technology Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Therapeutics Area
      • 8.3.2.2.2. By Technology
  • 8.3.3. Japan Pharmacogenomics Technology Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Therapeutics Area
      • 8.3.3.2.2. By Technology
  • 8.3.4. South Korea Pharmacogenomics Technology Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Therapeutics Area
      • 8.3.4.2.2. By Technology
  • 8.3.5. Australia Pharmacogenomics Technology Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Therapeutics Area
      • 8.3.5.2.2. By Technology

9. South America Pharmacogenomics Technology Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Therapeutics Area
  • 9.2.2. By Technology
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Pharmacogenomics Technology Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Therapeutics Area
      • 9.3.1.2.2. By Technology
  • 9.3.2. Argentina Pharmacogenomics Technology Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Therapeutics Area
      • 9.3.2.2.2. By Technology
  • 9.3.3. Colombia Pharmacogenomics Technology Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Therapeutics Area
      • 9.3.3.2.2. By Technology

10. Middle East and Africa Pharmacogenomics Technology Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Therapeutics Area
  • 10.2.2. By Technology
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Pharmacogenomics Technology Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Therapeutics Area
      • 10.3.1.2.2. By Technology
  • 10.3.2. Saudi Arabia Pharmacogenomics Technology Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Therapeutics Area
      • 10.3.2.2.2. By Technology
  • 10.3.3. UAE Pharmacogenomics Technology Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Therapeutics Area
      • 10.3.3.2.2. By Technology

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Pharmacogenomics Technology Market: SWOT Analysis

14. Competitive Landscape

• 14.1. QIAGEN N.V.
  • 14.1.1. Business Overview
  • 14.1.2. Product & Service Offerings
  • 14.1.3. Recent Developments
  • 14.1.4. Financials (If Listed)
  • 14.1.5. Key Personnel
  • 14.1.6. SWOT Analysis
• 14.2. GE HealthCare,
• 14.3. Agilent Technologies, Inc.
• 14.4. F. Hoffmann-La Roche Ltd
• 14.5. FOUNDATION MEDICINE, INC.
• 14.6. Thermo Fisher Scientific Inc.
• 14.7. Leica Biosystems Nussloch GmBH,
• 14.8. Pfizer Inc..

15. Strategic Recommendations

16. About Us & Disclaimer